Premium
Diagnosis of bladder cancer by analysis of the allelic loss of the p53 gene in urine samples using blunt‐end single‐strand conformation polymorphism
Author(s) -
Sugano Kokichi,
Tsutsumi Masakazu,
Nakashima Yuki,
Yamaguchi Kensei,
Ohkura Hisanao,
Kakizoe Tadao,
Sekiya Takao
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970822)74:4<403::aid-ijc7>3.0.co;2-z
Subject(s) - loss of heterozygosity , single strand conformation polymorphism , bladder cancer , locus (genetics) , urine , biology , microbiology and biotechnology , allele , gene , pathology , cancer , genetics , medicine , polymerase chain reaction , endocrinology
The novel approach of blunt‐end single‐strand conformation polymorphism (SSCP) has been applied in the analysis of urine samples from bladder‐cancer patients for detecting loss of heterozygosity (LOH) of 3 polymorphic markers in the p53 gene. Of the 28 urine samples examined by SSCP analysis of blunt‐ended DNA fragments using a fluorescence‐based automated sequencer, 16 were informative in more than 1 of the 3 polymorphic markers at the p53 locus and 8 (50.0%) showed allelic loss of the p53 gene. In analysis of resected tumor tissues, LOH of the p53 gene was detected in 8 of 8 informative samples (100%) with T1 and higher stages and/or Grade 2 and Grade 3 tumors, while it was detected in 6 (75.0%) urine samples obtained from these 8 patients. This new diagnostic modality enables sensitive detection of tumor cells in urine samples and would be applicable for diagnostic bladder cancer with invasive character. Int. J. Cancer 74:403–406, 1997. © 1997 Wiley‐Liss, Inc.